Lihua E. Budde

8.1k total citations · 3 hit papers
160 papers, 3.4k citations indexed

About

Lihua E. Budde is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Lihua E. Budde has authored 160 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Oncology, 82 papers in Pathology and Forensic Medicine and 36 papers in Immunology. Recurrent topics in Lihua E. Budde's work include CAR-T cell therapy research (108 papers), Lymphoma Diagnosis and Treatment (82 papers) and Chronic Lymphocytic Leukemia Research (29 papers). Lihua E. Budde is often cited by papers focused on CAR-T cell therapy research (108 papers), Lymphoma Diagnosis and Treatment (82 papers) and Chronic Lymphocytic Leukemia Research (29 papers). Lihua E. Budde collaborates with scholars based in United States, Canada and Australia. Lihua E. Budde's co-authors include Stephen J. Forman, Michael C. Jensen, Nancy L. Bartlett, Oliver W. Press, Brian G. Till, Xiuli Wang, Stanley R. Riddell, Jinjuan Wang, Yukang Lin and Tanya Siddiqi and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Lihua E. Budde

142 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

2017 463 citations Nancy L. Bartlett, Tanya Siddiqi et al. profile →
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

2012 431 citations Brian G. Till, Michael C. Jensen et al. Blood profile →
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

2022 244 citations Lihua E. Budde, Laurie H. Sehn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lihua E. Budde United States	25	3.0k	1.1k	917	734	659	160	3.4k
Brian G. Till United States	26	2.9k 1.0×	669 0.6×	1.0k 1.1×	988 1.3×	725 1.1×	135	3.5k
Tanya Siddiqi United States	29	2.5k 0.8×	1.6k 1.5×	777 0.8×	655 0.9×	449 0.7×	205	3.5k
Elise A. Chong United States	16	2.1k 0.7×	711 0.6×	638 0.7×	509 0.7×	472 0.7×	110	2.5k
Saad S. Kenderian United States	25	2.1k 0.7×	527 0.5×	790 0.9×	737 1.0×	647 1.0×	149	2.9k
Anthony R. Mato United States	24	1.9k 0.6×	1.1k 0.9×	619 0.7×	632 0.9×	462 0.7×	85	2.8k
Marco Ruella United States	29	3.2k 1.1×	374 0.3×	1.3k 1.4×	1.3k 1.7×	1.1k 1.6×	124	4.0k
Frederick L. Locke United States	34	5.2k 1.7×	977 0.9×	1.4k 1.5×	1.4k 1.9×	1.2k 1.8×	307	6.0k
Matthew J. Frigault United States	25	2.9k 1.0×	247 0.2×	851 0.9×	885 1.2×	717 1.1×	131	3.4k
Alex F. Herrera United States	28	2.5k 0.9×	2.1k 1.9×	642 0.7×	392 0.5×	196 0.3×	239	3.5k
Meng-Fen Wu United States	16	2.4k 0.8×	206 0.2×	1.0k 1.1×	815 1.1×	743 1.1×	18	2.9k

Countries citing papers authored by Lihua E. Budde

Since Specialization

Citations

This map shows the geographic impact of Lihua E. Budde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lihua E. Budde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lihua E. Budde more than expected).

Fields of papers citing papers by Lihua E. Budde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lihua E. Budde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lihua E. Budde. The network helps show where Lihua E. Budde may publish in the future.

Co-authorship network of co-authors of Lihua E. Budde

This figure shows the co-authorship network connecting the top 25 collaborators of Lihua E. Budde. A scholar is included among the top collaborators of Lihua E. Budde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lihua E. Budde. Lihua E. Budde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shouse, Geoffrey, Lu Chen, D. Lynne Smith, et al.. (2025). Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma. Leukemia & lymphoma. 66(14). 2790–2793.

Ladbury, Colton, Sagus Sampath, Jeffrey Wong, et al.. (2024). Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy. Frontiers in Immunology. 15. 1419788–1419788. 1 indexed citations

Bartlett, Nancy L., Laurie H. Sehn, Sarit Assouline, et al.. (2024). Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II. Blood. 144(Supplement 1). 1645–1645. 4 indexed citations

Rao, Shuquan, et al.. (2024). Revolutionizing genetic disease treatment: The case of exagamglogene autotemcel. The Innovation. 5(3). 100619–100619.

Burke, John M., Ian W. Flinn, Lihua E. Budde, et al.. (2024). Fixed-Duration Subcutaneous Mosunetuzumab Is Active and Has a Manageable Safety Profile in Patients with Previously Untreated, Low-Tumor Burden Follicular Lymphoma: Updated Results from the Phase II Morningsun Study. Blood. 144(Supplement 1). 3008–3008. 2 indexed citations

Budde, Lihua E., Don A. Stevens, Gary J. Schiller, et al.. (2024). Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.. Journal of Clinical Oncology. 42(16_suppl). 7077–7077.

Budde, Lihua E., Sarit Assouline, Laurie H. Sehn, et al.. (2024). Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of Clinical Oncology. 42(19). 2250–2256. 34 indexed citations

Gouni, Sushanth, et al.. (2024). Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma. American Society of Clinical Oncology Educational Book. 44(3). e433516–e433516. 10 indexed citations

Cao, Yang, et al.. (2023). Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting. Journal of Hematology & Oncology. 16(1). 69–69. 5 indexed citations

10.

Matasar, Matthew J., Nancy L. Bartlett, Mazyar Shadman, et al.. (2023). Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Clinical Lymphoma Myeloma & Leukemia. 24(4). 240–253. 10 indexed citations

11.

Ong, Shin Yeu, Matthew Mei, Leslie Popplewell, et al.. (2023). Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma. American Journal of Hematology. 98(11). 1751–1761. 17 indexed citations

12.

Aldoss, Ibrahim, Samer K. Khaled, M. Suzette Blanchard, et al.. (2022). Favorable Activity of CD19-Targeted Chimeric Antigen Receptor (CD19CAR) T Cell Therapy in Adults with Relapsed/ Refractory (R/R) ALL Including Extramedullary Disease (EMD) and Ph-like Genotype, Using Naive/Memory (Tn/ Mem) Derived T Cells. Transplantation and Cellular Therapy. 28(3). S201–S201. 1 indexed citations

13.

Saumoy, Monica, Yecheskel Schneider, Lihua E. Budde, et al.. (2022). Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood. 140(25). 2697–2708. 14 indexed citations

14.

Shah, Nina, Miguel‐Angel Perales, Cameron J. Turtle, et al.. (2021). Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic Malignancies. Future Oncology. 17(27). 3549–3560. 17 indexed citations

15.

Matasar, Matthew J., Chan Y. Cheah, Dok Hyun Yoon, et al.. (2020). Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood. 136(Supplement 1). 45–46. 27 indexed citations

16.

Poh, Christina, Paul Frankel, Christopher Ruel, et al.. (2019). Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 134(Supplement_1). 760–760. 25 indexed citations

17.

Herrmann, Andreas, Christoph Lahtz, Toshikage Nagao, et al.. (2017). CTLA4 Promotes Tyk2-STAT3–Dependent B-cell Oncogenicity. Cancer Research. 77(18). 5118–5128. 38 indexed citations

18.

Press, Oliver W., Philip Olsen, Sang Yun Lee, et al.. (2016). Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab. Cancer Immunology Research. 4(6). 509–519. 22 indexed citations

19.

Wang, Xiuli, ChingLam W. Wong, Ryan Urak, et al.. (2015). CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clinical Cancer Research. 21(13). 2993–3002. 52 indexed citations

20.

Till, Brian G., Michael C. Jensen, Jinjuan Wang, et al.. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 119(17). 3940–3950. 431 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact